Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
Open Access
Abstract
Despite the crucial advances in understanding the biology of cholangiocarcinoma (CCA) achieved during the last decade, very little of this knowledge has been translated into clinical practice. Thus, CCA prognosis is among the most dismal of solid tumors. The reason is the frequent late diagnosis of this form of cancer, which makes surgical removal of the tumor impossible, together with the poor response to standard chemotherapy and targeted therapy with inhibitors of tyrosine kinase receptors. The discovery of genetic alterations with an impact on the malignant characteristics of CCA, such as proliferation, invasiveness, and the ability to generate metastases, has led to envisage to treat these patients with selective inhibitors of mutated proteins. Moreover, the hope of developing new tools to improve the dismal outcome of patients with advanced CCA also includes the use of small molecules and antibodies able to interact with proteins involved in the crosstalk between cancer and immune cells with the aim of enhancing the immune system’s attack against the tumor. The lack of effect of these new therapies in some patients with CCA is associated with the ability of tumor cells to continuously adapt to the pharmacological pressure by developing different mechanisms of resistance. However, the available information about these mechanisms for the new drugs and how they evolve is still limited.Keywords
Funding Information
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (EHD15PI05/2016)
- Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (PI19/00819 and PI20/00189)
- Consejería de Educación, Junta de Castilla y León (SA074P20)
- Fundació Marató TV3 (201916-31)
- Fundación Científica Asociación Española Contra el Cáncer (2017/2020)
- Centro Internacional sobre el Envejecimiento (0348_CIE_6_E)
This publication has 115 references indexed in Scilit:
- No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver TumorsMolecular Pharmaceutics, 2012
- Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapyLung Cancer, 2012
- HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with LapatinibOncology, 2012
- Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracilWorld Journal of Gastroenterology, 2012
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaBritish Journal of Cancer, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBritish Journal of Cancer, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione S-Transferase-π-Specific Inhibitor O1-Hexadecyl-γ-glutamyl-S-benzylcysteinyl-D-phenylglycine EthylesterThe Journal of Pharmacology and Experimental Therapeutics, 2003
- High Expression of Thymidylate Synthase Leads to Resistance to 5‐Fluorouracil in Biliary Tract Carcinoma in vitroJapanese Journal of Cancer Research, 2001